Review





Similar Products

96
Addgene inc crispr cas9
Crispr Cas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/CRISPR-SP-Cas9+reporter+(Plasmid+%2362733)/bio_rxiv__64898__2026__11__04__762546-269-7-27
Average 96 stars, based on 1 article reviews
crispr cas9 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Addgene inc crispr cas9 plasmid pv1382
Crispr Cas9 Plasmid Pv1382, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/pV1382+(Plasmid+%23111436)/bio_rxiv__64898__2026__11__03__763959-245-1-9
Average 93 stars, based on 1 article reviews
crispr cas9 plasmid pv1382 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
Addgene inc crispr cas9 plasmid
Crispr Cas9 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/CRISPR-SP-Cas9+reporter+(Plasmid+%2362733)/pm42976007-252-5-19
Average 96 stars, based on 1 article reviews
crispr cas9 plasmid - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology plasmid mix expressing crispr cas9
Plasmid Mix Expressing Crispr Cas9, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/AIRE-1+CRISPR%2FCas9+KO+Plasmid/pmc13737429-43-12-22
Average 94 stars, based on 1 article reviews
plasmid mix expressing crispr cas9 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology muc16 knockout plasmid
KPC and <t>KPC-MUC16</t> KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16 KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16 KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16 KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16 KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16 KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16 KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.
Muc16 Knockout Plasmid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/Mucin+16+CRISPR%2FCas9+KO+Plasmid/pmc13756213-353-9-12
Average 94 stars, based on 1 article reviews
muc16 knockout plasmid - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Addgene inc crispr cas9 knockout cell lines
KPC and <t>KPC-MUC16</t> KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16 KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16 KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16 KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16 KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16 KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16 KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.
Crispr Cas9 Knockout Cell Lines, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/lentiCRISPR+v2+(Plasmid+%2352961)/pmc13693651-166-3-10
Average 96 stars, based on 1 article reviews
crispr cas9 knockout cell lines - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology cells
KPC and <t>KPC-MUC16</t> KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16 KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16 KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16 KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16 KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16 KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16 KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.
Cells, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/DZIP3+CRISPR%2FCas9+KO+Plasmid/pm42907603-375-1-9
Average 94 stars, based on 1 article reviews
cells - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

98
Addgene inc crispr cas9 technology
KPC and <t>KPC-MUC16</t> KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16 KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16 KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16 KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16 KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16 KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16 KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.
Crispr Cas9 Technology, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/lentiCRISPRv2+puro+(Plasmid+%2398290)/bio_rxiv__64898__2026__10__16__759525-186-4-8
Average 98 stars, based on 1 article reviews
crispr cas9 technology - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

96
Addgene inc px458 gfp crispr cas9 vectors
KPC and <t>KPC-MUC16</t> KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16 KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16 KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16 KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16 KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16 KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16 KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.
Px458 Gfp Crispr Cas9 Vectors, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+cas9+plasmids/pSpCas9(BB)-2A-Puro+(PX459)+V2%2E0+(Plasmid+%2362988)/pm42877069-424-17-25
Average 96 stars, based on 1 article reviews
px458 gfp crispr cas9 vectors - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


KPC and KPC-MUC16 KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16 KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16 KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16 KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16 KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16 KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16 KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.

Journal: Cancer letters

Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer

doi: 10.1016/j.canlet.2026.218927

Figure Lengend Snippet: KPC and KPC-MUC16 KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16 KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16 KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16 KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16 KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16 KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16 KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.

Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a MUC16 knockout plasmid (Santa Cruz, #sc-403050), and single-cell clones were selected and expanded as described previously [ 9 ].

Techniques: Immunostaining, Analysis, RNA Sequencing, Inhibition

A. Cytokine profile from tumor-conditioned media from T3M4 and T3M4-MUC16 KO cell lines; ELISA for CCL2 in tumor-conditioned media from B. T3M4 and T3M4-MUC16 KO and C. Capan-1 and Capan 1-MUC16 KO cells; RT-PCR for CCL2 and Serpin-E1 gene expression in D. KPC and KPC-MUC16 KO , E. T3M4 and T3M4-MUC16 KO , F. Capan-1 and Capan 1-MUC16 KO cells; Western blotting for p-AKT, total AKT, p-IKKα/β, IKKα, Serpin-E1, CCL2. GAPDH is used as a loading control in G. KPC and KPC-MUC16 KO and H. T3M4, T3M4-MUC16 KO , Capan-1 and Capan 1-MUC16 KO cells; Immunostaining for Serpin-E1 and representative histoscore graph, immunostaining for CCL2 and representative mean fluorescence intensity graph in I. GEMM and J. Orthotopic KPC and KPC-MUC16 KO mouse models; K. Chemotaxis of BMDMs towards control media (without cells) and KPC and KPC-MUC16 KO cells (n=5); L. Chemotaxis of BMDMs towards control media (without cells) (n=4), tumor-conditioned media from KPC and KPC-MUC16 KO cells, KPC conditioned media with CCL2, Serpin-E1 neutralization and dual neutralization (n=5). * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** p ≤ 0.0001

Journal: Cancer letters

Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer

doi: 10.1016/j.canlet.2026.218927

Figure Lengend Snippet: A. Cytokine profile from tumor-conditioned media from T3M4 and T3M4-MUC16 KO cell lines; ELISA for CCL2 in tumor-conditioned media from B. T3M4 and T3M4-MUC16 KO and C. Capan-1 and Capan 1-MUC16 KO cells; RT-PCR for CCL2 and Serpin-E1 gene expression in D. KPC and KPC-MUC16 KO , E. T3M4 and T3M4-MUC16 KO , F. Capan-1 and Capan 1-MUC16 KO cells; Western blotting for p-AKT, total AKT, p-IKKα/β, IKKα, Serpin-E1, CCL2. GAPDH is used as a loading control in G. KPC and KPC-MUC16 KO and H. T3M4, T3M4-MUC16 KO , Capan-1 and Capan 1-MUC16 KO cells; Immunostaining for Serpin-E1 and representative histoscore graph, immunostaining for CCL2 and representative mean fluorescence intensity graph in I. GEMM and J. Orthotopic KPC and KPC-MUC16 KO mouse models; K. Chemotaxis of BMDMs towards control media (without cells) and KPC and KPC-MUC16 KO cells (n=5); L. Chemotaxis of BMDMs towards control media (without cells) (n=4), tumor-conditioned media from KPC and KPC-MUC16 KO cells, KPC conditioned media with CCL2, Serpin-E1 neutralization and dual neutralization (n=5). * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** p ≤ 0.0001

Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a MUC16 knockout plasmid (Santa Cruz, #sc-403050), and single-cell clones were selected and expanded as described previously [ 9 ].

Techniques: Enzyme-linked Immunosorbent Assay, Reverse Transcription Polymerase Chain Reaction, Gene Expression, Western Blot, Control, Immunostaining, Fluorescence, Chemotaxis Assay, Neutralization, Positive Control

A. Experimental design for in vitro tumor cell and macrophage (BMDM) coculture; Flow cytometry quantification for B. iNOS+ CD86+ and C. CD206+ Arg-1+ macrophages in the KPC and KPC-MUC16 KO coculture at two ratios (1:1 or 2:1, macrophage: cancer cell); D. Experimental design for in vitro tumor conditioned media (CM) treatment on and BMDMs; Flow cytometry quantification for E. iNOS+ CD86+ and F. CD206+ Arg-1+ macrophages in control (media only), KPC and KPC-MUC16 KO conditioned macrophages, RT-PCR on control (media only), KPC and KPC-MUC16 KO conditioned macrophages for G. Arginase-1, H. IL-10, I. CXCL13, J. CD274, K. CD206, L. IL-1β expression. p values < 0.05 considered statistically significant.

Journal: Cancer letters

Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer

doi: 10.1016/j.canlet.2026.218927

Figure Lengend Snippet: A. Experimental design for in vitro tumor cell and macrophage (BMDM) coculture; Flow cytometry quantification for B. iNOS+ CD86+ and C. CD206+ Arg-1+ macrophages in the KPC and KPC-MUC16 KO coculture at two ratios (1:1 or 2:1, macrophage: cancer cell); D. Experimental design for in vitro tumor conditioned media (CM) treatment on and BMDMs; Flow cytometry quantification for E. iNOS+ CD86+ and F. CD206+ Arg-1+ macrophages in control (media only), KPC and KPC-MUC16 KO conditioned macrophages, RT-PCR on control (media only), KPC and KPC-MUC16 KO conditioned macrophages for G. Arginase-1, H. IL-10, I. CXCL13, J. CD274, K. CD206, L. IL-1β expression. p values < 0.05 considered statistically significant.

Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a MUC16 knockout plasmid (Santa Cruz, #sc-403050), and single-cell clones were selected and expanded as described previously [ 9 ].

Techniques: Expressing, In Vitro, Flow Cytometry, Control, Reverse Transcription Polymerase Chain Reaction

A. Experimental design for macrophage depletion using clodronate liposomes (and control neutral liposomes) in the orthotopic model. B. Tumor images upon euthanasia at day 21 post implantation for the following groups: KPC + control liposomes (n=5), KPC + clodronate liposomes (n=4), KPC-MUC16 KO + control liposomes (n=7), KPC-MUC16 KO + clodronate liposomes (n=6); Tumor C. Weight and D. Volume; E. H&E staining for tumor tissues from all groups (10x magnification); Staining and flow cytometry quantification for splenic macrophage populations – F. F4/80+ total macrophages, G. F4/80+ iNOS+ CD86+ M1-like macrophages, H. F4/80+ CD206+ M2-like macrophages, I. M1/M2 ratio, and intratumoral macrophage populations – J. F4/80+ total macrophages, K. F4/80+ iNOS+ CD86+ M1-like macrophages, L. F4/80+ CD206+ M2-like macrophages, M. M1/M2 ratio, in KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16 KO + control liposomes, KPC-MUC16 KO + clodronate liposomes tumor-bearing mice. p values < 0.05 considered statistically significant.

Journal: Cancer letters

Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer

doi: 10.1016/j.canlet.2026.218927

Figure Lengend Snippet: A. Experimental design for macrophage depletion using clodronate liposomes (and control neutral liposomes) in the orthotopic model. B. Tumor images upon euthanasia at day 21 post implantation for the following groups: KPC + control liposomes (n=5), KPC + clodronate liposomes (n=4), KPC-MUC16 KO + control liposomes (n=7), KPC-MUC16 KO + clodronate liposomes (n=6); Tumor C. Weight and D. Volume; E. H&E staining for tumor tissues from all groups (10x magnification); Staining and flow cytometry quantification for splenic macrophage populations – F. F4/80+ total macrophages, G. F4/80+ iNOS+ CD86+ M1-like macrophages, H. F4/80+ CD206+ M2-like macrophages, I. M1/M2 ratio, and intratumoral macrophage populations – J. F4/80+ total macrophages, K. F4/80+ iNOS+ CD86+ M1-like macrophages, L. F4/80+ CD206+ M2-like macrophages, M. M1/M2 ratio, in KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16 KO + control liposomes, KPC-MUC16 KO + clodronate liposomes tumor-bearing mice. p values < 0.05 considered statistically significant.

Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a MUC16 knockout plasmid (Santa Cruz, #sc-403050), and single-cell clones were selected and expanded as described previously [ 9 ].

Techniques: Liposomes, Control, Staining, Flow Cytometry, Formalin-fixed Paraffin-Embedded

Staining and flow cytometry for splenic T cell populations – A. CD3+ total T cells, B. CD3+ CD4+ helper T cells, C. CD3+ CD8+ cytotoxic T cells, D. CD3+ CD4+ FOXP3+ regulatory T cells, E. CD3+ CD4+ FOXP3+ CD25+ activated regulatory T cells; and intratumoral T cell populations – F. CD3+ total T cells, G. CD3+ CD4+ helper T cells, H. CD3+ CD8+ cytotoxic T cells, I. CD3+ CD4+ FOXP3+ regulatory T cells, J. CD3+ CD4+ FOXP3+ CD25+ activated regulatory T cells in KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16 KO + control liposomes, KPC-MUC16 KO + clodronate liposomes tumor-bearing mice. p values < 0.05 considered statistically significant.

Journal: Cancer letters

Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer

doi: 10.1016/j.canlet.2026.218927

Figure Lengend Snippet: Staining and flow cytometry for splenic T cell populations – A. CD3+ total T cells, B. CD3+ CD4+ helper T cells, C. CD3+ CD8+ cytotoxic T cells, D. CD3+ CD4+ FOXP3+ regulatory T cells, E. CD3+ CD4+ FOXP3+ CD25+ activated regulatory T cells; and intratumoral T cell populations – F. CD3+ total T cells, G. CD3+ CD4+ helper T cells, H. CD3+ CD8+ cytotoxic T cells, I. CD3+ CD4+ FOXP3+ regulatory T cells, J. CD3+ CD4+ FOXP3+ CD25+ activated regulatory T cells in KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16 KO + control liposomes, KPC-MUC16 KO + clodronate liposomes tumor-bearing mice. p values < 0.05 considered statistically significant.

Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a MUC16 knockout plasmid (Santa Cruz, #sc-403050), and single-cell clones were selected and expanded as described previously [ 9 ].

Techniques: Staining, Flow Cytometry, Control, Liposomes

A. UMAP clustering of cell types in orthotopic tumors from KPC (n=2) and KPC-MUC16 KO (n=2). B. Population analysis depicting percentages of cell types in KPC and KPC-MUC16 KO tumors. C. Spatial distribution of cell types including epithelial cells, dendritic cells, fibroblasts, endothelial cells, macrophages, proliferating immune cells and B cells in a KPC (sample 4690) and a KPC-MUC16 KO (sample 4342) tumor. D. Arginase-1 spatial gene expression in a KPC (sample 4690) and a KPC-MUC16 KO (sample 4342) tumor. Ligand-Receptor interaction modeling in KPC tumors (n=2) shown using a E. Heatmap depicting number of interactions between different cell types, F. Specific Ligand-Receptor pairs involved in macrophage-to-target cell crosstalk, G. Specific Ligand-Receptor pairs involved in source cell type-to-macrophage crosstalk. Ligand-Receptor interaction modeling in KPC-MUC16 KO tumors (n=2) shown using a H. Heatmap depicting number of interactions between different cell types, I. Specific Ligand-Receptor pairs involved in macrophage-to-target cell crosstalk, J. Specific Ligand-Receptor pairs involved in source cell type-to-macrophage crosstalk.

Journal: Cancer letters

Article Title: MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer

doi: 10.1016/j.canlet.2026.218927

Figure Lengend Snippet: A. UMAP clustering of cell types in orthotopic tumors from KPC (n=2) and KPC-MUC16 KO (n=2). B. Population analysis depicting percentages of cell types in KPC and KPC-MUC16 KO tumors. C. Spatial distribution of cell types including epithelial cells, dendritic cells, fibroblasts, endothelial cells, macrophages, proliferating immune cells and B cells in a KPC (sample 4690) and a KPC-MUC16 KO (sample 4342) tumor. D. Arginase-1 spatial gene expression in a KPC (sample 4690) and a KPC-MUC16 KO (sample 4342) tumor. Ligand-Receptor interaction modeling in KPC tumors (n=2) shown using a E. Heatmap depicting number of interactions between different cell types, F. Specific Ligand-Receptor pairs involved in macrophage-to-target cell crosstalk, G. Specific Ligand-Receptor pairs involved in source cell type-to-macrophage crosstalk. Ligand-Receptor interaction modeling in KPC-MUC16 KO tumors (n=2) shown using a H. Heatmap depicting number of interactions between different cell types, I. Specific Ligand-Receptor pairs involved in macrophage-to-target cell crosstalk, J. Specific Ligand-Receptor pairs involved in source cell type-to-macrophage crosstalk.

Article Snippet: MUC16 KO lines were generated using CRISPR-Cas9 using a MUC16 knockout plasmid (Santa Cruz, #sc-403050), and single-cell clones were selected and expanded as described previously [ 9 ].

Techniques: Spatial Transcriptomics, Activation Assay, Analysis, Gene Expression